挖掘复方丹参抑制卵巢癌细胞增殖及初步机制研究

目的：应用网络药理学及分子对接知识挖掘复方丹参对卵巢癌的抑制作用和机制。方法：本研究通过网络药理学挖掘复方丹参主要成分,应用分子对接技术研究复方丹参主要成分与治疗卵巢癌的核心靶点间的结合能力和形式、MTT比色法及流式细胞周期检测研究复方丹参的核心成分可能通过抑制EGFR所参与的信号通路从而抑制卵巢癌A2780细胞增殖作用。结果：基于网络药理学筛选出复方丹参的核心成分为木犀草素和槲皮素,疾病核心靶点为VEGFA、SRC、EGFR、HSP90AA1。通过分子对接验证及分析核心成分与核心靶点EGFR的对接模式,最后利用MTT比色法实验验证木犀草素具有明显抑制卵巢癌细胞的增殖作用,流式检测细胞周期实验结果表明木犀草素诱导卵巢癌A2780细胞周期阻滞于G1/S期。 结论：复方丹参制剂可发挥抑制卵巢癌细胞的增殖作用,且可能与EGFR介导的PI3K-Akt信号通路有关;网络药理学和分子对接技术对复方丹参治疗肿瘤具有重要的预测性及可能性,对复方丹参发挥抗卵巢癌细胞的作用及机制具有指导意义。

Study on the inhibition of compound salvia miltiorrhiza on the proliferation of ovarian cancer cells and its preliminary mechanism

AIM: To explore the inhibitory effect and mechanism of compound salvia miltiorrhiza on ovarian cancer by using network pharmacology and molecular docking knowledge. METHODS: The core components of compound salvia miltiorrhiza and the inhibitory effect of compound salvia miltiorrhiza on ovarian cancer cell cycle were studied by combining the methods of MTT cell cycle inhibition and MTT signal network of compound salvia miltiorrhiza. RESULTS: Based on network pharmacology, the core components of compound salvia miltiorrhiza were luteolin and quercetin, and the core target of the disease was VEGFA, SRC, EGFR, hsp90aa1. The docking mode between the core component and the core target EGFR was verified and analyzed by molecular docking. Finally, MTT colorimetry was used to verify that luteolin, one of the core components, significantly inhibited the proliferation of ovarian cancer cells. The results of flow cytometry showed that luteolin induced ovarian cancer A2780 cell cycle arrest in G1/S phase.CONCLUSION: Compound salvia miltiorrhiza preparation can inhibit the proliferation of ovarian cancer cells, which may be related to PI3K Akt signal pathway mediated by EGFR; Network pharmacology and molecular docking technology have important predictability and possibility for the treatment of tumor by compound salvia miltiorrhiza, and have guiding significance for the role and mechanism of compound salvia miltiorrhiza against ovarian cancer cells.